Efficacy and Safety of a New Dilution and Injection Volume of AbobotulinumtoxinA for the Treatment of Glabellar Lines

NCT03960957 · clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
301
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Galderma R&D